Epidemiology and Biology of Lung Cancer

R. Taylor Ripley, David R. Jones
Epidemiology and Biology of Lung Cancer is a topic covered in the Pearson's General Thoracic.

To view the entire topic, please log in or purchase a subscription.

STS Cardiothoracic Surgery E-Book from The Society of Thoracic Surgeons provides expert guidance for Cardiac and Thoracic Surgery. Sections include Pearson’s General Thoracic, Esphageal, Adult Cardiac, and Pediatric and Congenital Cardiac Surgery. Explore these free sample topics:

STS Cardiothoracic Surgery

Ventricular Septal Defects (VSD)Ventricular Septal Defects (VSD)

Laparoscopic Techniques in Reoperation for Failed Antireflux RepairLaparoscopic Techniques in Reoperation for Failed Antireflux Repair

Coronary Artery Bypass without CPBCoronary Artery Bypass without CPB

Diagnosis and Staging of Lung CancerDiagnosis and Staging of Lung Cancer

Nomenclature for Pediatric and Congenital Cardiac Care: Unification of Clinical and Administrative NomenclatureNomenclature for Pediatric and Congenital Cardiac Care: Unification of Clinical and Administrative Nomenclature

-- The first section of this topic is shown below --

Key Points

  • Lung cancer is the leading cause of cancer-related death, with a worldwide reported incidence of 1.83 million and mortality of 1.59 million.
  • The epidemiologic evidence of the association between tobacco smoke and lung cancer has become irrefutable, and investigations into the underlying biology have provided further support.
  • Lung cancer has one of the highest numbers of somatic mutations, resulting in genomic instability, which enables cancer development and progression.
  • The biology of lung cancer results in dysregulation of all of the hallmarks of cancer, including sustaining proliferative signaling, evading growth suppressors, resisting cell death, inducing angiogenesis, enabling replicative immortality, and activating invasion and metastasis.
  • The identification of oncogenic drivers through genomic analysis during the past decade has resulted in a paradigm shift in the treatment of non-small cell lung cancer (NSCLC), with targeted therapies and immunotherapy now in the forefront.
  • Despite advances in the understanding of the biology and in the treatment of lung cancer, overall survival (OS) remains low, which in part reflects the resistance that emerges during treatment.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

Key Points

  • Lung cancer is the leading cause of cancer-related death, with a worldwide reported incidence of 1.83 million and mortality of 1.59 million.
  • The epidemiologic evidence of the association between tobacco smoke and lung cancer has become irrefutable, and investigations into the underlying biology have provided further support.
  • Lung cancer has one of the highest numbers of somatic mutations, resulting in genomic instability, which enables cancer development and progression.
  • The biology of lung cancer results in dysregulation of all of the hallmarks of cancer, including sustaining proliferative signaling, evading growth suppressors, resisting cell death, inducing angiogenesis, enabling replicative immortality, and activating invasion and metastasis.
  • The identification of oncogenic drivers through genomic analysis during the past decade has resulted in a paradigm shift in the treatment of non-small cell lung cancer (NSCLC), with targeted therapies and immunotherapy now in the forefront.
  • Despite advances in the understanding of the biology and in the treatment of lung cancer, overall survival (OS) remains low, which in part reflects the resistance that emerges during treatment.

There's more to see -- the rest of this topic is available only to subscribers.

© 2023 The Society of Thoracic Surgeons and Unbound Medicine, Inc. All Rights Reserved.